MyFinsight
Home
Blog
About
Contact
Download
Download image
Total revenues
$294,282K
(benefit from) provision
for income taxes
-$245,197K
Net income (loss)
$367,024K
Net proceeds from
issuance of common stock...
$8,101K
Stock-based compensation
expense
$12,711K
Accounts payable
$3,852K
Depreciation and
amortization
$2,415K
Accrued compensation
$1,775K
Accrued research and
development
$1,451K
Revenue reserves and
refund liability
$1,276K
Lease liability
$724K
Canceled cashflow
$172,455K
Net cash provided by
(used in) operating...
$75,655K
Net cash provided by
(used in) financing...
$601K
Canceled cashflow
$315,573K
Canceled cashflow
$7,500K
Employee related
expenses
$75,314K
Commercial related
expenses
$25,898K
Cost of product sales
$19,621K
Outside clinical trial
related expenses
$18,307K
Consultants and third-party
services
$15,146K
Other segment items
$14,530K
Interest expense, net
-$3,639K
Net (decrease)
increase in cash, cash...
-$16,109K
Canceled cashflow
$76,256K
Maturities of short-term
investments
$61,129K
Deferred income tax
benefit
-$245,852K
Release of cost share
liability
$39,981K
Prepaid and other
current and non-current...
$11,848K
Accounts receivable, net
$10,148K
Inventories
$5,635K
Net amortization of
discount on short-term...
$1,150K
Right-of-use assets
-$674K
Other current and
long-term liabilities
-$285K
Principal payments of term
loans
$7,500K
Net cash (used in)
provided by investing...
-$92,365K
Canceled cashflow
$61,129K
Purchases of short-term
investments
$153,494K
Back
Back
Cash Flow
source: myfinsight.com
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)